LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oil Prices Climb on Venezuela Blockade, Russia Sanctions Fears, and Supply Risks 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
EU Delays Mercosur Free Trade Agreement Signing Amid Ukraine War Funding Talks 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Trump Orders Blockade of Sanctioned Oil Tankers, Raising Venezuela Tensions and Oil Prices 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty 
Asian Fund Managers Turn More Optimistic on Growth but Curb Equity Return Expectations: BofA Survey 
U.S. Stock Futures Slip After CPI-Fueled Rally as Markets Weigh Economic Uncertainty 
SK Plasma Co. Ltd. is building a new blood product plant with an investment of KRW300 billion or about $250 million. The facility is set to be constructed in Indonesia.
Once in full operation, the new plant is expected to have the capacity to produce one million liters of blood products per year. SK Plasma will break ground some time this year, and the plant will be completed in two years.
Business insiders revealed earlier this week that the South Korean firm that produces albumin, immunoglobulin, coagulation factors, and antithrombin received the final approval for the construction of its plant from the Ministry of Health and Welfare of Indonesia not long ago. The facility will process the collected blood plasma and turn them into therapeutic agents.
Business Korea reported that for this project, SK Plasma would partner with Infion through a joint venture (JV) agreement. It is an Indonesian pharmaceutical company that will SK Plasma with its business operation in the country.
The size of the company’s upcoming plant in Indonesia is said to have a bigger production capacity than its facility in Andong, South Korea. It will offer 1.6 times more than the 600,000-liter capacity of its Korean plant.
In any case, the new factory will produce six types of blood products like Liv Gamma and albumin. The Korea Herald reported that albumin and immune globulin, which will be produced at the SK Plasma Indonesian facility, are typically used for patients with hemophilia and immunodeficiency diseases. These are made through strict and rigorous processes, including the centrifugation of blood collected from blood donation drives.
The blood products will ensure a stable supply in Indonesia, where the population is already close to 300 million. It was said that 100% of the citizens are currently dependent on imports of blood products.
“By transferring technologies relating to blood products and installing a manufacturing facility in a country that has no related infrastructure, SK Plasma seeks to create new business opportunities and reach the company’s ESG goals,” Kim Seung Joo, SK Plasma’s chief executive officer, said in a statement.
